AIM Immunotech Inc. (AIM) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. AIM Immunotech Inc. is an immuno-pharma company focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders. Its flagship product, Ampligen (rintatolimod), is approved in Argentina for Chronic Fatigue Syndrome (CFS) but remains experimental in the U.S. The company is prioritizing clinical trials for pancreatic cancer and Post-COVID conditions. During the quarter, the company executed a 1-for-100 reverse stock split effective June 12, 2025, to regain compliance with NYSE American listing standards.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Value (in thousands) |
|---|---|
| Total Revenues | $41 |
| Net Loss | $(6,499) |
| Operating Loss | $(6,265) |
| Cash and Cash Equivalents (End of Period) | $476 |
| Marketable Investments | $359 |
| Total Current Assets | $1,025 |
| Total Current Liabilities | $10,393 |
| Working Capital Deficit | $(9,368) |
| Stockholders' Deficit | $(6,546) |
| Net Cash Used in Operating Activities | $(3,892) |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased to $41,000 for the six months ended June 30, 2025, from $90,000 in the prior year period, attributed to fluctuations in patient participation in the cost recovery program.
- Reduced Net Loss: Net loss improved to $6.5 million from $7.7 million in the prior year period, primarily driven by a $2.4 million reduction in General and Administrative (G&A) expenses and a $0.8 million decrease in R&D costs.
- Liquidity Deterioration: Cash and cash equivalents dropped from $1.7 million at year-end 2024 to $0.5 million at June 30, 2025. Marketable investments decreased from $2.3 million to $0.4 million.
- Debt Structure: The company entered into a new $250,000 promissory note in June 2025 and settled $450,000 of existing debt through the issuance of common stock.
Outlook, Risks, and Subsequent Events
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern due to recurring losses, a working capital deficit, and a stockholders' deficit of $6.5 million.
- Listing Status: Trading was suspended on the NYSE American in April 2025 due to low stock price. Following the reverse stock split, trading was reinstated on June 17, 2025. The company must maintain stockholders' equity of at least $6.0 million by June 11, 2026, to avoid delisting.
- Subsequent Financing: On July 30, 2025, the company closed a public offering raising $8.0 million in gross proceeds. Additionally, on August 1, 2025, the company repaid a Streeterville bridge note early for $285,000.
- Clinical Updates: The company suspended enrollment in its Phase 2 pancreatic cancer trial (AMP-270) as a business decision. Positive mid-year safety and efficacy updates were reported for the DURIPANC study (pancreatic cancer).
Investor Verification Checklist
- Verify the utilization of the $8.0 million raised in the July 2025 offering and its impact on the working capital deficit.
- Confirm the status of the NYSE American compliance plan and the timeline to achieve the required $6.0 million in stockholders' equity.
- Review the rationale and future plans regarding the suspension of the AMP-270 pancreatic cancer trial.
- Assess the sustainability of the cost recovery revenue model given the decline in patient participation.
- Monitor the debt obligations, specifically the Streeterville notes, and the terms of the new financing agreements.